

PRESS RELEASE

Ipca Laboratories Q2 FY16 Financial Results


Mumbai, October 30, 2015: Ipca Laboratories Limited today announced its unaudited standalone financial results for the second quarter and half year ended 30th September, 2015.

Key Financials of Q2 FY16

- Net Total Income down 4% at Rs. 754.48 crores.
- Indian formulations income up 1% at Rs. 330.75 crores.
- Exports Income down 7% at Rs. 374.59 crores.
- EBIDTA margin @ 11.90% as against @ 17.26% in Q2 FY15
- Net Profit at Rs. 11.69 crores down 81%.

Q2 FY16 at a glance			(Rs. Crores)
Particulars	Q2 FY16	Q2 FY15	Growth
Net Total Income	754.48	789.31	-4%
Export Income	374.59	402.44	-7%
EBITDA	89.16	134.77	-34%
EBIDTA Margin	11.90%	17.26%	-
Profit before Forex (gain) / loss and tax	43.78	98.13	-55%
Forex (gain) / loss	23.88	9.36	-
Net Profit after Forex (gain) / loss and tax	11.69	61.30	-81%
Earnings per share of Rs. 2/- each (Rs.)	0.92	4.86	-81%

Q2 FY16 Revenue break-up			(Rs. Crores)
Particulars	Q2 FY16	Q2 FY15	Growth
<u>Formulations</u>			
Domestic	330.75	327.91	1%
Exports	227.43	306.22	-26%
Total Formulations	558.18	634.13	-12%
<u>APIs</u>			
Domestic	33.24	44.54	-25%
Exports	147.16	96.22	53%
Total APIs	180.40	140.76	28%
Grand Total	738.58	774.89	-5%



Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Key Financials of H1 FY16


- Net Total Income down 12% at Rs. 1516.58 crores.
- Indian formulations income up 4% at Rs. 648.80 crores.
- Exports Income down 23% at Rs. 751.56 crores.
- EBITDA margin @ 11.37% as against @ 21.30% H1 FY15
- Net Profit at Rs. 30.58 crores down 85%.

H1 FY16 at a glance			(Rs. Crores)
Particulars	H1 FY16	H1 FY15	Growth
Net Total Income	1516.58	1731.56	-12%
Export Income	751.56	973.31	-23%
EBITDA	171.34	365.69	-53%
EBITDA Margin	11.37%	21.30%	-
Profit before Forex (gain) / loss and tax	82.54	278.45	-70%
Forex (gain) / loss	35.51	7.10	-
Net Profit after Forex (gain) / loss and tax	30.58	198.04	-85%
Earnings per share of Rs. 2/- each (Rs.)	2.42	15.69	-85%

H1 FY16 Revenue break-up			(Rs. Crores)
Particulars	H1 FY16	H1 FY15	Growth
Formulations			
Domestic	648.80	621.10	4%
Exports	452.26	693.95	-35%
Total Formulations	1101.06	1315.05	-16%
APIs			
Domestic	89.20	108.68	-18%
Exports	299.30	279.36	7%
Total APIs	388.50	388.04	-
Grand Total	1489.56	1703.09	-13%

About Ipca Laboratories:

Ipca is a pharmaceutical company with a strong thrust on exports which now account for 50% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.



Premchand Godha
Chairman & Managing Director

Encl: Unaudited Standalone Financial Results

Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22- 6210 6051

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837